Relationship between pancreatic hormones and glucose metabolism: A cross-sectional study in patients after acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 311: G50 -G58, 2016. First published May 12, 2016 doi:10.1152/ajpgi.00074.2016.-Abnormal glucose metabolism is present in almost 40% of patients after acute pancreatitis, but its pathophysiology has been poorly investigated. Pancreatic hormone derangements have been sparingly studied to date, and their relationship with abnormal glucose metabolism is largely unknown. The aim was to investigate the associations between pancreatic hormones and glucose metabolism after acute pancreatitis, including the effect of potential confounders. This was a cross-sectional study of 83 adult patients after acute pancreatitis. Fasting venous blood was collected from all patients and used for analysis of insulin, glucagon, pancreatic polypeptide, amylin, somatostatin, C-peptide, glucose, and hemoglobin A1c. Statistical analyses were conducted using the modified Poisson regression, multivariable linear regression, and Spearman's correlation. Age, sex, body mass index, recurrence of acute pancreatitis, duration from first attack, severity, and etiology were adjusted for. Increased insulin was significantly associated with abnormal glucose metabolism after acute pancreatitis, in both unadjusted (P ϭ 0.038) and adjusted (P ϭ 0.001) analyses. Patients with abnormal glucose metabolism also had significantly decreased pancreatic polypeptide (P ϭ 0.001) and increased amylin (P ϭ 0.047) in adjusted analyses. Somatostatin, C-peptide, and glucagon were not changed significantly in both unadjusted and adjusted analyses. Increased insulin resistance and reduced insulin clearance may be important components of hyperinsulinemic compensation in patients after acute pancreatitis. Increased amylin and reduced pancreatic polypeptide fasting levels characterize impaired glucose homeostasis. Clinical studies investigating islet-cell hormonal responses to mixed-nutrient meal testing and euglycemichyperinsulinemic clamps are now warranted for further insights into the role of pancreatic hormones in glucose metabolism derangements secondary to pancreatic diseases. acute pancreatitis; glucose metabolism; insulin; amylin; pancreatic polypeptide THE PANCREAS, A DUAL GLAND with both endocrine and exocrine functions, plays a key role in the development of both diabetes and pancreatitis. Diabetes mellitus (DM) is one of the most prevalent chronic diseases and contributes significantly to allcause worldwide mortality, with one in 12 adult deaths attributed to it (15a, 16). Acute pancreatitis (AP) is the most common cause of gastrointestinal-related hospitalizations in the Western countries, with over 270,000 patients requiring hospitalization each year in the United States alone (19). A recent comprehensive systematic review and meta-analysis of prospective clinical studies (11) showed that abnormal glucose metabolism (AGM) after an episode of AP is present in nearly 40% of patients without history of DM. Moreover, a large population-based study showed that patients after AP have a 2.5 times higher risk of developing newly diagnosed DM than individuals in the general population (32). Surveillance of high-risk patients with AP for prediabetes or diabetes would appear advisable (11, 32) .
the Western countries, with over 270,000 patients requiring hospitalization each year in the United States alone (19) . A recent comprehensive systematic review and meta-analysis of prospective clinical studies (11) showed that abnormal glucose metabolism (AGM) after an episode of AP is present in nearly 40% of patients without history of DM. Moreover, a large population-based study showed that patients after AP have a 2.5 times higher risk of developing newly diagnosed DM than individuals in the general population (32) . Surveillance of high-risk patients with AP for prediabetes or diabetes would appear advisable (11, 32) .
The pathophysiology of DM after AP has been poorly investigated, and the present evidential base is largely extrapolated from studies of glucose homeostasis in patients with other major pancreatic diseases, such as chronic pancreatitis (CP) and pancreatic cancer (28a, 31a) . Previous studies, most of which date back to the 1980s to 1990s, have suggested that the critical event in DM after CP and pancreatic cancer is insulin resistance (IR) and that it is related to pancreatic hormone abnormalities of not just insulin but also of glucagon and pancreatic polypeptide (4, 14) . Whether this holds true for DM after AP is unknown. To date, there have been no comprehensive clinical studies investigating changes in all pancreatic hormones and their derivatives (insulin, glucagon, C-peptide, amylin, pancreatic polypeptide, and somatostatin) after AP.
The aim of this study was to investigate the associations between a panel of pancreatic hormones and blood glucose metabolism after AP and the effect of potential confounders.
METHODS
Study design. The study was a cross-sectional follow-up study of patients with AP admitted to Auckland City Hospital (Auckland, New Zealand). Approval for the study was given by the Health and Disability Ethics Committee (13/STH/182) and the Auckland District Health Board (ADHB) Institution (Aϩ 6139).
Study population. Contact details for all eligible individuals were extracted from the ADHB clinical database (Concerto software, Orion Health Group). They were telephoned and invited to participate in the study. Individuals were eligible if they were at least 18 yr of age, had a primary diagnosis of AP based on the international guidelines (34) , resided in Auckland at the time of the study, and provided informed consent. For those individuals unable to visit the hospital, home visits by a certified phlebotomist were arranged.
In line with recent high-quality studies in the field of pancreatology, individuals were not considered eligible if they had CP, post-endoscopic retrograde cholangiopancreatography pancreatitis, intraoperative diagnosis of pancreatitis, pregnancy at time of AP or afterwards, malignancy, and diabetes or prediabetes (definitions below) before the first hospital admission attributable to AP.
Sample acquisition and storage. All study participants were required to fast for at least 8 h before the study. Patients were then accompanied to the International Accreditation New Zealand (IANZ) accredited tertiary referral medical laboratory, LabPlus, at Auckland City Hospital, where a certified phlebotomist collected venous blood into two EDTA tubes, one lithium heparin tube, one fluoride tube, and one plasma separation tube. Appropriate inhibitors were added to the samples where required (e.g., protease inhibitor cocktail for amylin and aprotinin for glucagon measurement). The tubes were centrifuged at 4,000 g for 7.5 min at 4°C, and the plasma was separated into 400-l aliquots. The Eppendorf tubes were then stored at Ϫ80°C until use.
Definitions. Individuals were identified as having normal glucose metabolism if their fasting blood glucose (FBG) was Ͻ5.6 mmol/l and/or glycated hemoglobin A1c (HbA1c) was Յ5.6% (38 mmol/ mol) (2) .
Individuals were identified as having AGM if they developed new prediabetes after AP, defined as FBG between 5.6 -6.9 mmol/l and/or HbA1c between 5.7-6.5% (39 -48 mmol/mol), or developed new diabetes after AP, defined as FBG Ն7.0 mmol/l and/or HbA1c Ն6.6% (49 mmol/mol), respectively (2) . These definitions were in line with recent high-quality studies of similar design in the field of diabetology (24, 27, 37) .
Body mass index (BMI) (kg/m 2 ) was determined using a digital medical scale with stadiometer. For height measurement (cm), study participants were asked to remove their shoes and any head attire. For weight measurement (kg), patients were asked to remove shoes, jacket, belt, and watch and to empty their pockets of all items.
Current smoking status was recorded as yes or no based on a questionnaire asking patients whether they smoked cigarettes or tobacco-related products on a daily basis.
Physical activity was recorded as active or inactive based on a questionnaire asking patients whether they did physical activity for at least 2.5 h/wk.
Recurrence of AP was defined as individuals admitted with one or more episodes of confirmed AP since their first admission with AP to the time of their participation in the study.
Severity was defined based on the Revised Atlanta Classification (8) .
Duration from first attack of AP was defined as the time (in mo) from the first hospital admission attributable to AP to the time of the study. The date of the first AP admission, for each patient, was obtained from the ADHB clinical database (Concerto software).
For the homeostasis model assessment of insulin resistance (HOMA-IR), glucose (mmol/l) and insulin (pmol/l) values were entered into the validated HOMA2 calculator (HOMA2 v2.2.3; Diabetes Trials Unit, University of Oxford) (20) to calculate IR for all patients.
For HOMA-%␤, glucose (mmol/l) and insulin (pmol/l) values were entered into the validated HOMA2 calculator (HOMA2 v2.2.3; Diabetes Trials Unit, University of Oxford) (20) to calculate the percentage of beta cell mass for each patient.
Laboratory assays. Blood tests for HbA1c, FBG, insulin, and anti-glutamic acid decarboxylase (GAD) antibodies were conducted at the IANZ accredited medical laboratory, LabPlus, at Auckland City Hospital. HbA1c was measured using the boronate affinity chromatography assay (Trinity Biotech). Chemiluminescence sandwich immunoassay was used to measure insulin (Roche Products and Roche Diagnostics NZ). An in vitro anti-GAD ELISA assay (Euroimmun AG) was used to quantify anti-GAD antibodies. FBG was measured using an enzymatic colorimetric assay (F. Hoffmann-La Roche).
Glucagon, pancreatic polypeptide, amylin, and C-peptide were measured using the MILLIPLEX MAP Human metabolic hormone magnetic bead panel based on the Luminex xMAP (Luminex) technology. Results were quantified (ng/ml) based on fluorescent reporter signals recorded by the Luminex xPONENT software (MILLIPLEX Analyst 5.1). All assays were performed as indicated in the user's manual.
Somatostatin was measured using the Merck-Millipore ELISA kits according to the user's manual. The Rayto Microplate Reader (V-2100C, Santa Fe) with an absorbance range of 405-630 nm was used to read the results (ng/ml).
A standard finger prick was performed on all patients to measure their fasting ketones.
Statistical analyses. The differences in baseline characteristics between participants with normal glucose metabolism and those with AGM were evaluated using the 2 test. All data were presented either as median and interquartile range, mean and SD, or frequency. The subsequent statistical analyses were conducted in four steps.
First, with all the statistical assumptions met, the association between conventional risk factors for type 2 DM and prevalence of AGM was investigated using the modified Poisson regression (9, 39) . The analysis was adjusted for the following covariates: age, sex, ethnicity, etiology, BMI, smoking, physical activity, recurrence of AP, severity, duration from first AP attack, HOMA-IR, and HOMA-%␤. The lowest category for all covariates was set as the reference. All data were reported as unstandardized ␤-coefficients with corresponding 95% confidence intervals (CI).
Second, Spearman's correlation (') was used to investigate the correlations of pancreatic hormones and their derivatives.
Third, multivariable unadjusted and adjusted linear regression analyses were performed to study the association between the conventional risk factors for type 2 DM and the pancreatic hormones. All statistical assumptions for linear regression, in particular homoscedasticity and multicollinearity, were met. Each pancreatic hormone was analyzed individually as a continuous dependent variable. An unadjusted model, investigating the association between risk factors and pancreatic hormone, was conducted before an adjusted regression analysis. The adjusted analysis included demographics (age, sex, and ethnicity) as covariates. Bonferroni correction was used to prevent overfitting of the data. All data were presented as unstandardized ␤-coefficients with corresponding 95% CI.
Fourth, a modified Poisson regression analysis, using the Generalized Linear Model, was used to investigate the association between each pancreatic hormone and AGM. Pancreatic hormones were categorized into quartiles based on predetermined concentration ranges calculated using the frequency function. The P trend across the quartiles was then calculated by assigning each participant the median value in their quartile and evaluating this as a continuous variable. Each pancreatic hormone was investigated as an independent variable in one unadjusted and three adjusted models. The unadjusted model investigated the association between each pancreatic hormone and prevalence of AGM. Model 1 was then adjusted for demographics. This was followed by model 2, which was adjusted for all covariates (age, sex, etiology, recurrence, severity, ethnicity, smoking, physical activity, BMI, and duration from first attack of AP). Covariates found to be significant in model 2 for each pancreatic hormone individually were then adjusted for in model 3. For the purpose of this analysis, the offset value was set as 1. A main-effects model was fit for both unadjusted and adjusted models to derive the most conservative estimates. Pearson's 2 was fit as the scale parameter, accounting for any overdispersion. A robust estimator for covariance matrix was selected to obtain the most robust estimates. All data were presented as prevalence ratios (PR) with corresponding 95% CI. All analyses were conducted using SPSS for Windows Version 23. P Ͻ 0.05 was accepted as statistically significant in all analyses.
RESULTS
A total of 83 individuals after AP were recruited into the study. The baseline characteristics of all study participants are shown in Table 1 . Women constituted 40% of the entire cohort, and the average age was 51 Ϯ 15 yr. The study participants were followed up after an average of 26 mo since their first attack of AP. Of 83 individuals, 30 (36%) developed AGM and had significantly higher FBG, HbA1c, and HOMA-IR (Table  1) . Ketones did not differ significantly between individuals with and without AGM (P ϭ 0.276). None of the patients in the entire cohort was anti-GAD antibody positive.
The associations between risk factors for type 2 DM and AGM after AP are shown in Table 2 . Of the studied factors, age (␤ ϭ 0.01; 95% CI ϭ 0.00, 0.01; P ϭ 0.001), severity (␤ ϭ 0.23; 95% CI ϭ 0.10, 0.36; P ϭ 0.001 for moderate AP), ethnicity (␤ ϭ 0.19; 95% CI ϭ 0.02, 0.36; P ϭ 0.027; and ␤ ϭ Ϫ0.19; 95% CI ϭ Ϫ0.31, Ϫ0.06; P ϭ 0.004, for Asian and other Europeans, respectively), HOMA-IR, and HOMA-%␤ (␤ ϭ 0.30; 95% CI ϭ 0.19, 0.40; P Ͻ 0.001, and ␤ ϭ Ϫ0.01; 95% CI ϭ Ϫ0.03, Ϫ0.01; P Ͻ 0.001, respectively) were found to have a significant association with AGM. Other factors were not significantly associated with AGM after AP.
The correlations between the six pancreatic hormones studied are shown in Table 3 . Strong positive correlations were found between pancreatic polypeptide and glucagon (' ϭ 0.64; P Ͻ 0.001), C-peptide and glucagon (' ϭ 0.63; P Ͻ 0.001), and C-peptide and pancreatic polypeptide (' ϭ 0.40; P ϭ 0.001). C-peptide and insulin, amylin and insulin, glucagon and insulin, and somatostatin and glucagon were also found to have statistically significant correlations (P Ͻ 0.001; P ϭ 0.003; P ϭ 0.047; P ϭ 0.036, respectively).
The associations between risk factors for type 2 DM and each pancreatic hormone are shown in Table 4 . Of the studied factors, severity, physical activity, BMI, and ethnicity were found to have significant associations with at least one pancreatic hormone. Severity of AP was significantly associated with insulin in both the unadjusted and adjusted models (P ϭ 0.010 and P ϭ 0.007, respectively), and with pancreatic polypeptide in the unadjusted model only (P ϭ 0.023). Physical activity had significant negative associations with insulin, amylin, and C-peptide in both the unadjusted (P ϭ 0.041, P ϭ 0.032, and P ϭ 0.007, respectively) and adjusted models (P ϭ 0.019, P ϭ 0.007, and P ϭ 0.001, respectively). BMI was significantly and positively associated with insulin and C-peptide (P Ͻ 0.001 and P ϭ 0.041, respectively) in the unadjusted model and with insulin only in the adjusted model (P Ͻ 0.001). Ethnicity was significantly associated with pancreatic polypeptide in both the unadjusted (P ϭ 0.004) and adjusted (P ϭ 0.004) models.
The associations between pancreatic hormones and AGM are shown in Table 5 . Insulin, pancreatic polypeptide, and amylin were associated with higher prevalence of AGM (Table  5) . Compared with the lowest quartile of insulin, a PR (95% CI) of 2.48 (1.08, 5.68; P trend ϭ 0.038) in the highest quartile was most different in the unadjusted model, followed by a PR of 2.08 (1.06, 4.07; P trend ϭ 0.039) in model 1, a PR of 1.46 (1.25, 1.69; P trend ϭ 0.001) in model 2, and a PR of 1.34 (1.15, 1.57; P trend ϭ 0.003) in model 3. Amylin was not associated with AGM in the unadjusted model. However, the highest quartile differed significantly from the lowest quartile with a PR of 1.41 (1.15, 1.72; P trend ϭ 0.047) in model 2.
Pancreatic polypeptide was not associated with AGM in the unadjusted model. However, it was found to significantly decrease from lowest quartile to the highest quartile with a PR of 0.73 (0.62, 0.87; P trend ϭ 0.001) in model 2 and 0.81 (0.68, 0.98; P trend ϭ 0.004) in model 3.
Glucagon, C-peptide, and somatostatin were not significantly associated with AGM after AP in any of the models (Table 5) .
DISCUSSION
To date, this is the most comprehensive clinical study on glucose metabolism after AP that investigated the role of an exhaustive panel of pancreatic hormones and the effect of risk factors on pathological changes in blood glucose control after AP. The findings are important in identifying the derangements of glucose homeostasis that occur after an episode of AP. Furthermore, they may help identify early patients with AP who are at high risk of developing new-onset DM after hospital discharge.
Most experts in the field believe that increased IR and resulting compensatory hyperinsulinemia are the key early pathological mechanisms of altered glucose homeostasis after pancreatic diseases (5, 11a, 18a, 35, 36 ). Our study supports this by showing that IR, as determined by HOMA-IR, was significantly associated (P Ͻ 0.001) with increased risk of AGM after AP. What is new here is that, although insulin levels were increased in individuals with AGM both in the unadjusted and the adjusted models, C-peptide levels remained unchanged in all the models (Table 5 ). This suggests that compensatory hyperinsulinemia after AP is achieved, not by increased insulin secretion from pancreatic beta cells, but rather by reduced removal of insulin from the circulation, a notion known as insulin clearance (38) . Similar findings were reported in an earlier study of 20 patients with CP that found reduced insulin clearance (38) . However, it must be acknowledged that C-peptide has a longer half-life than insulin, which may limit the accuracy of estimating insulin secretion in the present study. Deconvolution-method or two-compartment mathematical models should ideally be used to accurately quantify the changes in beta cell function (10) . Detailed physiological characterization studies to measure insulin-related changes after AP are needed to test the hypothesis that both increased IR and reduced insulin clearance are critical early events in the pathogenesis of DM after AP.
The other notable finding is that pancreatic polypeptide was significantly associated with AGM after AP (Table 5) . Pancreatic polypeptide, a 36-amino-acid peptide, is released from the pancreatic polypeptide cells (31) . It inhibits pancreatic exocrine secretion, food intake, gastric emptying, and gallbladder contraction (31) . Although the majority of previous studies have investigated meal-induced pancreatic polypeptide secretion, several studies in the settings of both pancreatic diseases and type 2 DM have studied fasting pancreatic polypeptide. Earlier studies have consistently demonstrated that pancreatic polypeptide (both fasting and meal-induced) is decreased in patients with CP both without and with coexisting DM (3, 22) . The findings are conflicting in the type 2 DM literature where one study reported significantly decreased fasting pancreatic polypeptide levels after 12 wk from hospital discharge (18) , and another reported a 10-fold increase in patients with type 2 DM compared with healthy controls (23) . Moreover, recent guidelines state that an absent pancreatic polypeptide response to a mixed meal is a specific indicator of impaired glucose homeostasis after CP and pancreatic cancer (30) . This study takes the field further by demonstrating, for the first time, that fasting pancreatic polypeptide is decreased in patients with AGM after AP. Only two clinical studies in the 1980s investigated pancreatic polypeptide in the setting of AP. The studies (13, 33 ) that included 8 and 17 patients with AP, respectively, found that fasting pancreatic polypeptide levels were within the normal range shortly after hospital admission. However, they did not follow up patients, and the sample sizes were very small. A clinical study is now warranted to investigate pancreatic polypeptide response to a mixed meal in patients after AP and its association with blood glucose metabolism. Changes in concentration of amylin were also found to be significantly associated with AGM after AP. Amylin is cosecreted with insulin from pancreatic beta cells in a 20:1 molar ratio of insulin to amylin, and its physiological role is to suppress glucagon secretion, which in turn prevents hepatic glucose release, decreases gastric emptying, and stimulates satiety (21) . Consistent with these, unadjusted and adjusted models in this study showed very similar trends for insulin and amylin, with the highest quartile differing significantly from the lowest quartile with a PR of 2.48 and 1.41, correspondingly, and a negative correlation between amylin and glucagon (' ϭ Ϫ0.20). To date, however, only two clinical studies have investigated amylin in patients with pancreatitis. One study included 57 patients with chronic alcoholic pancreatitis and 20 healthy subjects and found that fasting plasma amylin levels were significantly higher in patients with chronic alcoholic pancreatitis (15) . Furthermore, patients with CP and AGM had significantly higher amylin levels compared with patients with CP and normal glucose metabolism. The second study included 12 patients with AP and found that amylin levels correlated with hyperglycemia, IR, and severity of AP on day 3 after diagnosis of AP (29) . Taken together, these studies suggest that amylin may play an important role in blood glucose metabolism after pancreatitis.
This study also sheds more light on risk factors for DM after AP and their associations with changes in pancreatic hormones. Although factors such as BMI, age, smoking status, and physical activity have long been associated with increased risk of type 2 DM (26), risk factors for DM after AP have been studied inconclusively and inconsistently (6, 12) . Results from our multivariate analyses show that age was significantly associated with increased risk of AGM after AP, with 1 yr of increase in age leading to a 1% increase in risk of developing AGM after AP. Of the AP-related factors, only severity was significantly associated with AGM, with 23% increased risk of developing AGM after moderate AP. Investigation of associations between pancreatic hormones and risk factors showed that physical activity was significantly associated with insulin, amylin, and C-peptide in both unadjusted and adjusted analyses. BMI was found to be significantly associated with insulin and C-peptide in unadjusted analyses, but only insulin remained significantly associated in adjusted analyses. On the Data are presented as ␤-coefficients [95% CI]; adjusted model for age, sex, and ethnicity was adjusted for sex and ethnicity, age and ethnicity, and age and sex, respectively. All other adjusted models were adjusted for age, sex, and ethnicity simultaneously. Significant (P Ͻ 0.05) associations are shown in bold. basis of the above findings, it appears that not all of the major risk factors for type 2 DM contribute to blood glucose derangements after AP. Of all AP-related risk factors, only severity of AP was found to be significantly associated with insulin, in both unadjusted and adjusted models, and with pancreatic polypeptide in the unadjusted model only.
The study has several strengths. First, this study followed a uniform protocol and used the most up-to-date international definitions for all patients. In particular, AGM was defined by both FBG and HbA1c, using the American Diabetes Association thresholds. This makes it the largest study on blood glucose control after AP that employed the most robust diagnostic criteria used in the field of diabetology (6, 12, 28, 35) . The diagnostic criteria for AP were also robust and based on the International Association of Pancreatology/American Pancreatic Association guidelines (34) . This is important because many of the previous studies relied on diagnostic discharge codes for AP, the use of which results in at least 20% misclassification bias. Furthermore, unlike many other studies (6, 12, 28, 35) we were careful to exclude patients with preexisting AGM, CP, pancreatic cancer, and pancreatic surgery. Second, the study provides a unique insight into pathophysiology of blood glucose metabolism after AP, as none of the patients received any blood glucose-lowering therapy (25) , which would be expected to modify the disease course. Third, in line with modern literature, modified Poisson regression (1) and linear regression analyses with multilevel modeling were used in this study to obtain the most robust and accurate estimates. This approach is superior to both logistic regression and binomial regression for this type of study (9) . Last, this study takes into account the potential confounding effect of obesity and severity of AP on glucose homeostasis after AP by adjusting all the studied associations for BMI and degrees of severity. To date, only two studies in the field of AP have adjusted their estimates for obesity (17, 35) and none for severity of AP, as defined by modern severity classifications (28b-28d) .
This study has several limitations. First, because of the cross-sectional study design, no inferences can be drawn as to whether the changes in pancreatic hormones cause derangements in blood glucose metabolism or are consequences of them. Hence, this study is considered hypothesis generating, and its findings need to be tested in well-designed prospective longitudinal studies. Second, given the large study sample size, the blood parameters investigated were in fasting patients only. This is suboptimal for studying the islet cell hormones involved in regulation of glucose homeostasis. In the future, mixed-nutrient meal testing and very detailed phenotyping studies, such as the euglycemic-hyperinsulinemic clamp or the frequently sampled intravenous glucose tolerance test, are warranted in high-risk patients to unveil dynamic alterations of glucose homeostasis after AP. Third, C-peptide may not be the most accurate measure of insulin secretion. Future studies should use the deconvolution c Model 2 for all pancreatic hormones was adjusted for age, BMI, duration from first attack of acute pancreatitis, sex, ethnicity, etiology, recurrence, severity, smoking, and physical activity.
d Model 3 of insulin was adjusted for severity, ethnicity, smoking, exercise, and age. e Model 3 of glucagon was adjusted for ethnicity, smoking, severity, age.
f Model 3 of pancreatic polypeptide was adjusted for severity, ethnicity, and age. g Model 3 of amylin was adjusted for severity, etiology, ethnicity, smoking, and age.
h Model 3 of somatostatin was adjusted for severity, etiology, ethnicity, smoking, age, and BMI. i Model 3 of C-peptide was adjusted for severity, ethnicity, and age. method or two-compartment mathematical model to accurately quantify the changes in insulin secretion and action (10) . Last, although we did our best to exclude from this study all individuals with preexisting glucose abnormalities, it is possible that AP had triggered a response in genetically susceptible individuals with covert derangements of glucose homeostasis. Adult-onset autoimmune diabetes, based on the presence of islet-specific autoantibodies to GAD, insulin, insulinoma-associated protein 2, and zinc transporter antigen, has been reported after pancreatic diseases in general, and AP in particular (7) . However, none of the participants in this study were found to be anti-GAD antibody positive.
In conclusion, the present study shows that increased IR and reduced insulin clearance may be important components of hyperinsulinemic compensation in patients after AP. Impaired glucose homeostasis after AP is characterized by increased fasting levels of amylin and reduced fasting levels of pancreatic polypeptide. Age and severity of AP appear to be the most important risk factors for developing glucose derangements after AP.
